Drugs / Rina-S
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05579366 | Dec 2022 → Jul 2027 expected | breast adenocarcinoma, cervical cancer, endometrial cancer, fallopian tube cancer +5 | Genmab | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07539311 | May 2026 → Sep 2028 expected | digestive system cancer | Genmab | Recruiting | No outcome recorded |
| Phase 2 | NCT07288177 | Jan 2026 → Nov 2027 expected | non-small cell lung carcinoma | Genmab | Recruiting | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT07859215 | Nov 2026 → Mar 2030 expected | ovarian carcinoma | Genmab | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07564141 | Aug 2026 → Dec 2029 expected | ovarian cancer | Genmab | Recruiting | No outcome recorded |
| Phase 3 | NCT07604766 | Jun 2026 → Sep 2027 expected | refractory malignant neoplasm | Genmab | Recruiting | No outcome recorded |
| Phase 3 | NCT07225270 | Apr 2026 → Oct 2028 expected | ovarian cancer | Genmab | Recruiting | No outcome recorded |
| Phase 3 | NCT07166094 | Nov 2025 → Aug 2029 expected | endometrial cancer | Genmab | Recruiting | No outcome recorded |
| Phase 3 | NCT06619236 | Feb 2025 → Aug 2026 overdue | refractory malignant neoplasm | Genmab | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-10-03 | Genmab | Results Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer genmab.com ↗
Genmab A/S (Nasdaq: GMAB) today announced results from Part C of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC), demonstrated that among 109 treated patients with platinum-resistant ovarian cancer (PROC), Rina-S achieved a confirmed objective response rate (ORR) of 45.9% (95% CI: 36.3–55.7), including five complete responses (CRs) and a median duration of response (mDOR) of 12.1 months (95% CI: 6.5–15.4), with 51% of responders remaining in response at one year. |
All press releases naming this drug 1 release
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rina-S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07225270 ↗ |
| Modality | Other / unclassified | “a folate receptor alpha (FRα) targeted antibody-drug conjugate” NCT05579366 ↗ |
| Route | Intravenous | “Intravenous infusion of Rina-S” NCT05579366 ↗ |